Loading clinical trials...
Loading clinical trials...
The investigators focused on patients with refractory acute leukemia or MDS and designed a phase 1 trial of escalated cladribine doses in the Cla-Flu-Bu RTC regimen using PK-guided myeloablative busul...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Institut Paoli-Calmettes
NCT07216443 · Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and more
NCT06852222 · Leukemia, Myeloid, Acute
NCT06580106 · Leukemia, Myeloid, Acute
NCT06649253 · Leukemia, Lymphoblastic, Acute, Pediatric
NCT06501196 · Leukemia, Leukemia, Myeloid, and more
Institut Paoli-Calmettes
Marseille, Bouches-du-Rhône
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions